What you state is true. Joe and the team have kept
Post# of 36537
(Total Views: 279)
Posted On: 12/29/2020 6:31:19 AM
What you state is true. Joe and the team have kept us going and we should appreciate that aspect. Shareholder value has taken a tremendous hit along the way.
Hard to say how much the SEC audit affected Generex. That audit has been over a while and where have we gotten? The question too is why was the SEC having to do such a deep audit? I don't recall ever seeing why the audit was triggered or why it took so long. Your memory is way better than mine, do you recall?
Anyway, moving into 2021 is challenging as Covid will continue to hamper business for the near to mid term future. Whatever non vaccine research revenue comes in will be modest unless something new comes along.
What I desire from GNBT/NGIO "soon", say by Jan 15th-20th is a clearly defined plan for this next year.
A simple thing but I would appreciateaudio and printed transcripts of all the past and future CC's to be available for review.
Also a suggestion for the CC's and I apologize this is another CYDY thing. The length of our CC's is burdensome. I don't have an hour and a half or longer to be on a call. We have repeat and long winded questions. I don't need to hear how long someone has been a shareholder or what interested them to buy shares. CYDY has investors put questions in through the website. The companies attorney organizes the questions and fires them to the CEO. The CEO answers some but turns others over to the CFO or Chief Medical/Scientific officer. When the CEO is done answering he says "next question" and the attorney moves on to the next question. Having the attorney, CFO and CMO/CSO in addition to the CEO available to answer provides clearer answers and provides more legitimacy to the process. CYDY gets though more questions in less time this way. They also are allowed to clarify each other's answers when needed and it has happened a few times. I appreciate that aspect a fair bit. There could still be a live Q&A session at the end if time allows.
Go GNBT and NGIO!
Hard to say how much the SEC audit affected Generex. That audit has been over a while and where have we gotten? The question too is why was the SEC having to do such a deep audit? I don't recall ever seeing why the audit was triggered or why it took so long. Your memory is way better than mine, do you recall?
Anyway, moving into 2021 is challenging as Covid will continue to hamper business for the near to mid term future. Whatever non vaccine research revenue comes in will be modest unless something new comes along.
What I desire from GNBT/NGIO "soon", say by Jan 15th-20th is a clearly defined plan for this next year.
A simple thing but I would appreciateaudio and printed transcripts of all the past and future CC's to be available for review.
Also a suggestion for the CC's and I apologize this is another CYDY thing. The length of our CC's is burdensome. I don't have an hour and a half or longer to be on a call. We have repeat and long winded questions. I don't need to hear how long someone has been a shareholder or what interested them to buy shares. CYDY has investors put questions in through the website. The companies attorney organizes the questions and fires them to the CEO. The CEO answers some but turns others over to the CFO or Chief Medical/Scientific officer. When the CEO is done answering he says "next question" and the attorney moves on to the next question. Having the attorney, CFO and CMO/CSO in addition to the CEO available to answer provides clearer answers and provides more legitimacy to the process. CYDY gets though more questions in less time this way. They also are allowed to clarify each other's answers when needed and it has happened a few times. I appreciate that aspect a fair bit. There could still be a live Q&A session at the end if time allows.
Go GNBT and NGIO!
(4)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼